Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

Trodella, Lucio; Marinis, Filippo de; D’Angelillo, Rolando Maria; Ramella, Sara; Cesario, Alfredo; Valente, Salvatore; Nelli, Fabrizio; Migliorino, Maria Rita; Margaritora, Stefano; Corbo, Giuseppe Maria; Porziella, Venanzio; Ciresa, M.; Cellini, Francesco; Bonassi, Stefano; Russo, Patrizia; Cortesi, Enrico; Granone, Pierluigi

doi:10.1016/j.lungcan.2006.07.020

Cited by 8 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was received by 51.6% of patients, which increased to 77.3% in the case of SCLC. There is a generalized increasing trend to use chemotherapy treatment in LC, either on its own or combined with other therapeutic options, being based on studies which have demonstrated a clinical benefit with this in detriment to palliative treatments (Trodella et al 2006). The surgery was performed in a low percentage of patients in our series, probably related to the large number of patients who were diagnosed for the first time in advanced stages and the high comorbidity they had at the time of diagnosis.…”

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lung cancer in a health area of Spain: incidence, characteristics and survival

Prim

Barcala

Esquete

et al. 2010

European Journal of Cancer Care

View full text Add to dashboard Cite

To examine the incidence, characteristics, therapeutic approach and survival of diagnosed lung cancer (LC) in the Santiago de Compostela Health Area. A retrospective study was carried out on LC for a period of 3 years. Of the 481 cases collected, 92.7% were male. The median age was 66.93 years. The crude incidence for men and women was 80.71 and 5.84 per 100,000 inhabitants respectively. Among the non-small cell lung cancers (NSCLC), 68.1% were diagnosed in stage IIIB or IV. The cancer had already spread in 62.2% of the small cell lung cancer (SCLC). Chemotherapy was used in 51.6% of patients. The survival probability from the first to the fifth year was 47.7%, 24.3%, 12.9%, 10% and 8.9% respectively. The median survival at 5 years was 12.12 months for NSCLC, rising to 29.8 months in stage I, and 8.85 months in SCLC. In our Health Area LC occurs more often in men, in whom the prevalence of smoking is very high. The most common histology type was squamous cell carcinoma. In the majority of cases, the diagnosis is made in the advanced stages, which accounts for the low percentage of surgical treatments and the short survival.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Lung cancer in a health area of Spain: incidence, characteristics and survival

Prim

Barcala

Esquete

et al. 2010

European Journal of Cancer Care

View full text Add to dashboard Cite

show abstract

“…Moreover, gemcitabine dosage in the concurrent chemoradiotherapy schedule was 600 mg/m 2 [6], which was nearly twice the recommended dosage in phase I studies [7]. Furthermore, in more recent reports, the weekly gemcitabine dosage concurrently with involved-field radiotherapy have been shown to be associated with low and acceptable toxicity [8, 9]. …”

Section: Predisposing Factors For Radiation-induced Esophagitismentioning

confidence: 99%

Esophagitis, Treatment-Related Toxicity in Non-Small Cell Lung Cancer

Bar‐Ad¹,

Ohri²,

Werner‐Wasik³

2012

RRCT

View full text Add to dashboard Cite

Objectives Radiation esophagitis represents a significant complication experienced by non-small cell cancer (NSCLC) patients receiving thoracic irradiation. The objective of the current review was to assess the clinical and dosimetrical parameters that may predict radiation esophagitis. Methods Studies were identified by searching PubMed electronic databases. Both prospective and retrospective studies were included. Information regarding clinical and dosimetrical parameters predicting for radiation-induced esophagitis was extracted and analyzed. Results The esophageal clinical and dosimetric parameters that best predict acute esophagitis remain unclear. In many reports, Vx (the volume of esophagus receiving x Gy) stands out, with values of x ranging from 20–70 Gy. Other studies conclude that the maximal dose received by any point of the esophagus is the best predictor of esophagitis. Another metric implicated with esophageal toxicity in some reports is the proportion of the esophageal circumference or surface area that receives high doses of radiation. Conclusions Technological advancements in patient immobilization, setup verification, and radiotherapy delivery are increasingly being employed to limit the toxicity of thoracic irradiation. Future efforts are required to determine how these complex techniques should best be implemented to minimize the risks of acute and long-term esophageal injury.

show abstract

“…Chemotherapy helps radiotherapy to reduce the number of tumor cells by an average logarithm of 2-3 52 . Several studies have reported induction chemotherapy response rate ranging from 46% to 82% [53][54][55] . So, in selected bulky disease, induction chemotherapy can be useful to reduce the radiotherapy target volume, which is strictly correlated with toxicity.…”

Section: Chemotherapy For Nsclcmentioning

confidence: 99%